It does sound a very interesting development, and potentially a solution for type 2s who have suffered pancreatitis or pancreas burn-out after over-medication with gliclazide. However, I wonder whether the autoimmune system that kills the pancreas' beta cells would also kill the new insulin producing cells in the liver the same way? I.e. would they attack wherever insulin is produced or do they only target the pancreas?